Immupharma PlcLSE: IMM

Notice of AGM

· Issued by Immupharma Plc
Watch Immupharma explain itIMMUPHARMA PLC (IMM) — Corporate Update · Replay · Mar 20

 20 May 2025

ImmuPharma PLC

("ImmuPharma" or the "Company")

Notice of AGM & Annual Report & Accounts

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting ("AGM") has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2024 has also been posted to shareholders today.

These documents will be available shortly, in electronic form, for download on the Company's website www.immupharma.co.uk.

ImmuPharma's AGM will be held on Thursday 12th June 2025 @ 11:00am (BST) at: The Malmaison Hotel, 18-21 Charterhouse Square, Barbican, London EC1M 6AH.

Ends

For further information please contact:

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman and Chief Executive Officer

+ 44 (0) 207 206 2650

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Stanford Capital Partners (Joint Broker)

Patrick Claridge, Bob Pountney

SI Capital (Joint Broker)

Nick Emerson

+44 (0) 203 368 3550

+44 (0) 203 815 8880

+44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140, is a unique non-immunosuppressive peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895